Answers are grounded in this paper and cite their sources.
Anastrozole is an aromatase inhibitor (AI) used as adjuvant therapy for breast cancer. Anastrozole is subject to direct glucuronidation catalyzed by UDP-glucuronosyltransferase1A4 (UGT1A4). Interindividual variability in anastrozole glucuronidation may be affected by UGT1A4 SNPs. Interplay between drug metabolizing genes such as UGT1A4 and transporter genes may also be affected by genetic variability. Thus, we hypothesize that genetic variability in MRPs could influence anastrozole glucuronidation.
No takes yet. Share an insight, caveat, or question.
Edavana Vineetha Koroth (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: